Referral Sources
Community oncologists refer once biomarker testing finds a KRAS, NPM1 or KMT2A change, and leukemia patients often arrive through transplant centers. Patients with pancreatic cancer frequently search for RAS studies themselves.
Patients Exploring Targeted Inhibitors Want to Match With You
Patients who know their mutation are looking for the practices that treat it. Make yours easy to find, and easy to choose.
Patients swipe on the practices they like. When you swipe back — it’s a match!
Free to join. No card required.
Who’s Looking
The Patients Searching for RAS and Menin Inhibitors
More patients now arrive knowing their biomarker: KRAS G12C, a pancreatic KRAS mutation, NPM1. They are searching for practices that offer the approved inhibitors and the trials reaching the mutations that are not yet covered.
On Health e Match they list their diagnosis, their history and that they are exploring targeted therapy, and they meet practices that treat what they listed.
Typical Patient
An adult who knows their mutation, has had at least one line of therapy and is looking for an approved targeted option or a study for a mutation not yet covered.
Your Profile
Show Patients What You Offer
Your profile is where a patient decides. Describe RAS and menin inhibitors the way you offer it, your clinicians and their credentials, and the regulatory status of each therapy in your own words.
- Mutations You Treat. The specific alterations your approved therapies and studies address.
- Biomarker Testing. The tissue and blood tests you order, and how you handle outside results.
- Studies Enrolling Now. Pan-RAS, next-generation and menin inhibitor studies, with phase and status.
- Monitoring Plan. The visits and labs a patient on oral targeted therapy should expect.
- Regulatory Status. Approved and investigational options, shown separately and exactly.
Why Practices Join
Warm Patients, Not Cold Leads
-
Patients Make the First Move
They read your profile and swipe on you first. You’re notified the moment one does.
-
You Choose Your Patients
Swipe back on the ones who fit your practice. Pass on the ones who don’t.
-
Your Credentials Do the Talking
Your NPI is checked against the national registry, and your license and coverage are reviewed before you go live.
-
Nothing Rings the Front Desk
Messaging takes place on healthematch.com, after you’ve swiped back.
Questions
What Practices Ask
Can we list both approved inhibitors and trials?
Yes. Each therapy carries the regulatory status you document, and patients see it exactly as you wrote it.
Can patients share their biomarker?
Patients describe their diagnoses and history in their own profile, and you see it once they have chosen your practice.
Do leukemia and solid-tumor patients find the same practice?
They find the practices that treat what they listed. If you treat both, describe both, so each patient sees their own condition reflected.
Can we say a study is for patients whose cancer progressed on an approved inhibitor?
Yes. Describing who a study is for, as your approved materials do, helps the right patients choose you and saves both sides time.
Start Matching Today
Build your practice profile once, list RAS and menin inhibitors among what you offer, and let patients who are looking for it choose you.
Free to join. No card required.
healthematch.com makes introductions between patients and practices in the United States. It does not provide medical advice, diagnosis, or treatment, does not recruit for or enroll anyone in clinical research, and does not recommend any particular procedure or provider. A practice listing an investigational therapy remains responsible for its own study’s recruitment and eligibility requirements. Looking for care? See the RAS and menin inhibitors page for patients.